Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco

BETHESDA, Md., Jan. 11  /PRNewswire-FirstCall/ -- Spherix Inc. (NASDAQ: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its President, Dr. Robert Lodder, will be presenting at the Annual OneMedPlace Finance Forum, which is being held at the Sir Francis Drake Hotel in San Francisco, CA.  Dr. Lodder will deliver the Company's corporate presentation on Tuesday, January 12th, at 2:00 PM PT. Dr. Lodder will also deliver the corporate presentation on Wednesday, January 13th, at 2:00 PM PT at the EBD Biotech Showcase, which is being held at the Marines' Memorial Club & Hotel in San Francisco, CA.

Spherix is an emerging leader in the development of therapies for diabetes, atherosclerosis and the metabolic syndrome.  The company is actively developing D-tagatose as a novel, oral compound for the treatment of Type 2 diabetes, and recently announced positive interim results from its ongoing Phase 3 clinical trial being conducted both in the US and internationally.

Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners.  Over 100 company presentations will occur by some of the most promising -- and typically least recognized -- companies in the world.

The EBD Biotech Showcase was launched in January 2009. Focused on biotechnology, the showcase allows private and public presenting companies an opportunity to speak to an audience of investors and biopharmaceutical business development executives during the course of the largest annual healthcare investor conference.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research.  The company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is currently running a Phase 3 clinical trial to study the use of D-tagatose as a treatment for Type 2 diabetes.  Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides.  For more information, please visit http://www.spherix.com/.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934.  Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007.  Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events. 

DATASOURCE: Spherix Incorporated



CONTACT:  Investor Relations, Spherix Incorporated, [phone],





Web Site:  http://www.spherix.com/ 

Copyright